Evidence map›Paper›PMID 36523741›Full record

ReviewCureus2022

The Evolution of Hypertension Guidelines Over the Last 20+ Years: A Comprehensive Review.

Endurance O Evbayekha, Okelue E Okobi, Tobechukwu Okobi, Emeka C Ibeson, Jane N Nwafor, Oyintoun-Emi Ozobokeme, Adedoyin Olawoye, Ihuoma A Ngoladi, Maureen G Boms, Faridah A Habib and 5 more

Abstract readReview
In one paragraph

Review in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Endurance O EvbayekhaInternal Medicine, St. Luke's Hospital, Chesterfield, USA.
Okelue E OkobiFamily Medicine, Arizona State University, Tempe, USA.
Tobechukwu OkobiInternal Medicine, BronxCare Health System, New York City, USA.
Emeka C IbesonInternal Medicine, Maimonides Medical Center, New York City, USA.
Jane N NwaforInternal Medicine, University of DC, Silver Spring, USA.
Oyintoun-Emi OzobokemeMedicine, Central Michigan University College of Medicine, Mount Pleasant, USA.
Adedoyin OlawoyeInternal Medicine, Maimonides Medical Center, New York City, USA.
Ihuoma A NgoladiFamily Medicine, Private Practice, Calgary, CAN.
Maureen G BomsClinical Research, University of Alabama at Birmingham, Birmingham, USA.
Faridah A HabibFamily Medicine, Alberta International Medical Graduates Association (AIMGA), Calgary, CAN.
Babatunde O OyeladeCardiology, Emory University, Atlanta, USA.
Caroline C OkoroaforFamily Medicine, University of Calabar, Calabar, NGA.
Vivian N ChukwumaInternal Medicine, University of Illinois at Chicago/Advocate Christ Medical Center, Chicago, USA.
Kesena B AlexFaculty of Medicine, University of London, London, GBR.
Evidence E OhikhuaiPublic Health, Jackson State University School of Public Health, Jackson, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypertension is the most common modifiable risk factor for cardiovascular and cerebrovascular diseases. In the last two decades, the guidelines have evolved tremendously from areas with no recommendations for screening or treatment to targeted recommendations for some at-risk groups. We sought to go through the literature that provided guidelines for the management of hypertension at any point in time over the last 22 years from 2000 to 2022. We searched four databases: PubMed, Embase, Google Scholar, and Cochrane, using specified search terms. The keywords used were "hypertension" and "guidelines." We combined them using the Boolean operators (AND, OR) and searched for articles. A total of 2461 publications were initially identified; 348 publications were excluded after screening for full-text availability. The full-text articles were further filtered based on title and abstract screening. Following this, a total of 1443 articles were excluded. The remaining 670 full-text articles were assessed for eligibility. Of the 670 full-text articles, 480 were excluded based on exclusion criteria, and following the full-text article screening, 190 articles met the final inclusion criteria. Most of these guideline evolutions concerned establishing and adjusting thresholds for the subgroups of the elderly population and patients with diabetic kidney disease, chronic kidney disease, and stroke. Furthermore, the medications of choice are now guided by the stage of disease, presence or absence of comorbidities, and other relevant information, as opposed to ethnicity, which was previously a heavy yardstick for medication choice.

Indexed as

cardiovascular diseaseguidelinesheart healthhypertensionhypertensive heart diseasereview

Identifiers

PMID36523741
PMCPMC9746526

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.